U nilateral primary aldosteronism (PA) is a common surgically curable cause of secondary hypertension. Adrenal glands removed for unilateral PA display histological heterogeneity. Recently, gain-of-function somatic mutations in KCNJ5, ATP1A1, ATP2B3, CACNA1D, and CTNNB1 have been found in 50% to 80% of aldosterone-producing adenomas (APAs).
a heterogeneous cell composition. 3, 5 Both were multicenter studies that accrued large number of patients through different ascertainment methods.
This study, therefore, aims to characterize the histopathologic spectrum of APAs by genotype and their proliferation rate. To diminish subjectivity, ZG-like and ZF-like cell compositions were based on the presence or absence of CYP17A1 (as a ZF cell marker). The proliferation marker Ki67 was used to determine the proliferation rate of the mutant adenoma. Past studies of Ki67 staining in neoplastic adrenocortical cells successfully differentiated the highly proliferating carcinomas (labeling index ≥2.5%) from the nonmalignant functioning and nonfunctioning adenomas (labeling index ≤1%). 16, 17 Through this study, histopathology-genotype correlations of APAs were verified objectively, and a newly identified CACNA1D mutation was characterized.
Methods

Study Design
APA diagnosis was confirmed through immunohistochemistry (IHC) staining of CYP11B2 using the selective mouse monoclonal antibody (gifted by Prof Celso Gomez-Sanchez, University of Mississippi Medical Center). Confirmed APAs that had sufficient material for tumor and adjacent normal adrenal DNA extraction (n=28) were target sequenced for mutations in hot spots of causal genes for PA. Hot spots were regions of exons in a gene that had previously been published to contain causal mutations associated with APA pathology. 1, [4] [5] [6] 11, 13, [18] [19] [20] The IHC staining of CYP17A1 in APAs was compared with their adjacent peritumoral ZF to determine ZG-like or ZF-like cell composition of APA. This was done using the selective rabbit polyclonal CYP17A1 antibody (also gifted by Prof Celso Gomez-Sanchez). Intense IHC nuclei staining of Ki67 was used to determine the proliferation rate of mutant adenoma. This was done using a selective commercial ready-to-use mouse monoclonal antibody (Catalog No. IR62661, Dako, Denmark). The percentage of the adenoma that were compact cells (ie, low cytoplasm to nucleus ratio) was characterized using hematoxylin and eosin-stained sections of all APAs as a marked difference between ZF cells and ZG cells is the higher cytoplasm to nucleus ratio. This was done by a histopathologist blinded to the genotype and immunohistochemical results. Genotype and APA histology were correlated with patients' clinical characteristics and demography and APAs' CYP17A1 and Ki67 staining. Novel mutations found in hot spots of causal genes were functionally validated.
Subjects
Individuals with unilateral PA were recruited from the University Hospital Hradec Kralove (n=39). Subjects gave written informed consent for genetic investigation, which was approved by the University Hospital Hradec Kralove Ethics Committee. Case detection and subtype identification were in accordance with local guidelines described in detail previously. 21, 22 Confirmation and lateralization of PA were performed as detailed in Methods in the online-only Data Supplement. This cohort of subjects had previously been reported separately for another study.
11 Therein, 6 KCNJ5 mutant APAs, 4 ATP1A1 mutant APAs, and 3 CACNA1D mutant APAs were initially identified in the cohort through Taqman genotyping (n=39) and microfluidic sequencing (n=18).
Phenotyping of Adrenal Sections by Pathologists
Hematoxylin and eosin-stained sections of APAs were examined by a histopathologist blinded to the clinical phenotype and genotype. Semiquantitative assessments of the APA compact cell composition were made (compact cells were defined as having a cytoplasm to nucleus ratio of ≤1). Percentage of atypical cells, mitotic figures, and spironolactone bodies, if any, were also noted. Representative fields of the APAs' histology were photographed.
IHC Staining Method
IHC staining was performed on formalin-fixed paraffin-embedded tissue sections using the detection antibody system EnVision FLEX+, Mouse, High pH (Dako, Denmark) according to manufacturer's recommendations. The parameters detailed in the online-only Data Supplement were used for the different primary antibodies (Table  S1 in the online-only Data Supplement). Negative controls were performed by omitting the primary antibody. Positive control tissues were stained with every batch, ensuring antibodies were specific and selective in all IHC experiments ( Figure S1 ). IHC staining of CYP11B2 and CYP17A1 were scored blindly by a histopathologist 0 to 10 representing 0% expression to 100% expression (details in Table S2 ). APAs were then categorized as ZG-like or ZF-like based on the CYP17A1 score; ZF-like APAs had to have a score >5, whereas ZG-like APAs had a score of ≤5. Intense Ki67 nuclei staining was quantified by Image J using a previously published semiautomated image analysis of high-contrast tissue areas method (further detailed in Methods in the online-only Data Supplement).
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DNA Analysis
DNA was extracted from formalin-fixed paraffin-embedded tissue sections using ReliaPrep FFPE gDNA Miniprep System (Promega, USA) according to manufacturer's recommendation. Samples for DNA extraction were macrodissected from serial sections of CYP11B2 IHC-stained sections, limiting selection to adenoma tissue expressing aldosterone synthase. The primers from Table S3 were used to amplify and sequence hot spots in KCNJ5, ATP1A1, ATP2B3, CACNA1D, and CTNNB1.
Complementary DNA Constructs
Human wild-type (WT) Ca v 1.3α 1 subunits (reference sequence EU363339) comprising alternative exons 8a and 42 (long C-terminal splice variant) or 43s (short C-terminal splice variant) were previously cloned into the pGFP minus vector (no GFP [green fluorescent protein] tag, cytomegalovirus promoter). 24, 25 Mutation V1153G was introduced into both Ca v 1.3 splice variants using standard polymerase chain reaction approaches, and the complete sequence of the mutated α 1 -subunit was verified by DNA sequencing (Eurofins Genomics, Germany).
Cell Culture and Transfection
tsA-201 cells were maintained in culture and transiently transfected with WT or mutant Ca v 1.3 α 1 -and auxiliary β 3 -(NM_012828) and α 2 δ-1-(NM_001082276) subunits as previously described. 26 GFP was cotransfected to visualize transfected cells.
Electrophysiological Recordings in tsA-201 Cells
All recordings were performed at room temperature (21-23°C) in whole-cell configuration using the Axopatch 200B amplifier (Axon instruments), digitized at 50 kHz (Digitizer 1322A; Axon instruments), low-pass filtered at 5 kHz, and compensated for 60% to 90% of the series resistance. Specific details are provided in Methods in the online-only Data Supplement.
Statistical Analysis
All data are presented as mean±SEM for the indicated number of experiments (n) unless stated otherwise. Electrophysiology data were analyzed using Clampfit 10.2 (Axon Instruments, Inc), Microsoft Excel, SigmaPlot 8 (Systat Software, Inc), and GraphPad Prism 5 (GraphPad software, Inc). Statistical tests were performed using standard statistical software, and the statistical significance was set at P value <0.05. Normally distributed data were compared using unpaired Student's t test, and non-normally distributed data were compared using Mann-Whitney U test. Comparison of sex between genotypes was performed with Fisher exact test. Analysis of covariance was performed to adjust for differences in age, sex, and antihypertensive medicines between groups.
Results
Targeted Sequencing of APAs
In the 28 samples that had an identifiable APA with sufficient material for further analysis, targeted sequencing at hot spots of causal APA genes found 10 APAs to have a KCNJ5 mutation (35.7%), 7 APAs to have an ATP1A1 mutation (25%), and 4 APAs to have a CACNA1D mutation (14.3%; Table S4 ). One novel mutation was identified in exon 28 of CACNA1D (V1153G) located in segment 6 of transmembrane repeat III, representing a highly conserved region which is part of the channel's alleged activation gate ( Figure S2 ).
Characterization of Newly Identified CACNA1D Mutation V1153G
To investigate the pathogenic relevance of this novel mutation, the mutation was introduced into 2 major C-terminal long and short Ca v 1.3 splice variants and characterized by whole-cell patch-clamp recordings. Mutation V1153G did not significantly alter current densities through the channel but showed a tendency toward higher current amplitudes in the short splice variant ( Figure 1A and 1C). However, mutation V1153G shifted voltage dependence of activation in both splice variants by ≈−10 mV, enabling mutant channels to activate at more negative potentials than WT channels. In addition, V1153G shifted voltage dependence of inactivation in both splice variants toward more negative potentials ( Figure 1B and 1D and Table 1 ) and also slowed inactivation in response to prolonged depolarization (Figure 1E and 1F; Table S5 ). When introduced into the long splice variant, V1153G channels had significantly less steadystate inactivation ( Figure 1B) . Along with the hyperpolarizing shift of the voltage dependence of activation, this is expected to result in an increased window current in the C-terminal long splice variant. Taken together, these gating changes are characteristic for CACNA1D gain-of-function mutations.
APA Cell Histology and IHC Staining
For CYP17A1 expression, ATP1A1 and CACNA1D mutant APAs had a low IHC score, whereas KCNJ5 mutant APAs had a high IHC score (1 [1] [2] Figure 2 ). For CYP11B2 expression, the differences were less marked but still significant, with ZG-like ATP1A1 and CACNA1D mutant APAs having a higher score than KCNJ5 mutant APAs (9 [6-10] versus 6 [2] [3] [4] [5] [6] [7] ; P value =0.03; Table 2 and Figure 2 Figure S4 and Figure  S5 ). Two ATP1A1 mutant APAs and 1 CACNA1D mutant APA Table 1 and Table S5 .
had >30% nuclei with moderate Ki67 staining ( Figure S3 ). To note, ZG-like APAs (inclusive of ATP1A1/CACNA1D mutant APAs) had monomorphic bland nuclei, whereas ZF-like APAs (inclusive of KCNJ5 mutant APAs) frequently had atypical cells with large nuclei and prominent nucleoli ( Figure 3 ; Table  S4 ). Spironolactone bodies were found in 2 CACNA1D mutant APAs and 1 ZG-like WT APA (Table S4) .
Patient Profile
ZG-like APAs frequently occurred in older male patients (Table 3) . This was mainly because of an ATP1A1 mutation (6 males, 1 female; average age 60±3 years). Although there was no significant difference in blood pressure, patients with an ATP1A1 or CACNA1D mutant APA were on a higher number of antihypertensive medications compared with patients with a KCNJ5 mutant APA (4±0.3 versus 3±0.4; P value =0.02), implying a more therapy-resistant form of hypertension. The number of antihypertensive medications post-adrenalectomy was not significantly different between genotypes (Table S6) . Differences in CYP17A1 score, percent of compact cells, and Ki67 score remain significant after controlling for age, sex, and antihypertensive medications (Table S7) .
Discussion
Herein we showed that KCNJ5, ATP1A1, and CACNA1D mutant APAs in our cohort had a seemingly specific histopathologic phenotype-with KCNJ5 mutant APAs having a strong expression of CYP17A1 (an enzyme highly expressed in the ZF but not the ZG) and ATP1A1/CACNA1D mutant APAs having predominantly negative expression of CYP17A1. Interestingly, it was the smaller ATP1A1/CACNA1D mutant APAs that had the higher proliferation rate as represented by the expression of Ki67 in the cells nuclei. KCNJ5 mutant APAs, on the other hand, frequently had atypical cells with large nuclei and prominent nucleoli, which were pronouncedly absent in ATP1A1/CACNA1D mutant APAs.
In our white cohort, 35.7% had a KCNJ5 mutation, 25% had an ATP1A1 mutation, and 14.3% had a CACNA1D mutation. Of the CACNA1D mutations, 1 was novel, in exon 28-a substitution of the valine amino acid at position 1153 to glycine. This mutation is adjacent to previously reported mutations found in APAs, V1151F and I1152N ( Figure S2 ). 5 We found that the V1153G mutation causes a gain-of-function in the voltage-dependent calcium channel Ca V 1.3. This involved a hyperpolarizing shift of the voltage dependence of activation and inactivation for the channel and slower inactivation kinetics in both long and short major C-terminal Ca v 1.3 splice variants. We have previously reported that other Ca V 1.3 mutations inducing similar gating changes increase aldosterone production in human adrenocortical cells. 27 Taken together, our data reveals that V1153G induce gating changes characteristic for APA and other gain-of function CACNA1D mutations, 28 providing strong evidence for a pathogenic role of this mutation. Through classifying APAs as ZG-like or ZF-like based on expression of a ZF marker, CYP17A1, we found ATP1A1 and CACNA1D mutations to only occur in ZG-like APAs, whereas KCNJ5 mutations only occurred in ZF-like APAs. Comparing the percentage of compact cells, ZG-like APAs classified based on lack of CYP17A1 expression were on average 50% compact cells, whereas ZF-like APAs classified based on high CYP17A1 expression were on average 0% compact cells. This finding could explain why other studies 3, 5 that used only cell composition (ie, hematoxylin and eosin staining) to categorize an APA as ZG-like or ZF-like found ATP1A1 and CACNA1D mutant APAs to have a heterogeneous cell composition. As for the finding of KCNJ5 mutations in ZF-like APAs, this is already well accepted, supported further by the recent findings of high levels of hybrid steroids, 18-oxocortisol and 18-hydroxycortisol, in patients with KCNJ5 mutant APA, which requires the combined presence of the steroid enzyme CYP11B2, with the ZF hallmark enzymes CYP11B1 and CYP17A1 3, 5, [11] [12] [13] [14] [15] 29 .
In a meta-analysis of 1636 patients from 13 studies, Lenzini et al 30 showed that patients with a KCNJ5 mutant APA were more frequently female, diagnosed at a younger age, and had a higher plasma aldosterone concentration and a larger tumor than those with a WT KCNJ5 APA. One could deduce that the young diagnosis age and high steroid levels may be both caused by the large size of the tumor and the high plasma aldosterone concentration. Taking into account this meta-analysis, we surprisingly found KCNJ5 mutant APAs to have a low expression of CYP11B2 (needed to synthesize aldosterone) and low expression of Ki67 (a proliferation marker) compared with CACNA1D/ATP1A1 mutant APAs and ZG-like WT APAs. The relatively high levels of aldosterone concentration in patients with KCNJ5 mutations considering the low levels of CYP11B2 expressed in these APAs could be explained simply by the larger tumor size of the KCNJ5 mutant APA. Indeed, the study by Monticone et al 14 showed that if CYP11B2 expression was corrected for tumor volume, a significant positive correlation with plasma aldosterone was seen. Alternatively, the findings of atypical cells with large nuclei and prominent nucleoli in ZF-like APAs in this study and in Scholl et al's study 3 could suggest that these cells are assembling ribosomes to actively synthesize large amounts of protein. Thus, unlike ZG-like APAs, which have monomorphic bland nuclei, one could postulate that KCNJ5 mutant APAs continuously undergo steroidogenesis, which would account for the high aldosterone (and hybrid steroid levels), despite the low expression of the CYP11B2. Thus, the presence of atypically large nucleus in ZF-like APAs when mitotic activity is low warrants further interrogation.
The low expression of Ki67 found in KCNJ5 mutant APAs suggest that the larger tumor size of KCNJ5 mutant APA is because of the larger size of a ZF-like cell rather than because of the mutant APAs having a high proliferation rate. Indeed a ZG-like APA has approximately twice the number of cells than a ZF-like APA in a same sized section because of the high cytoplasm to nucleus ratio of ZF-like cells. Further, the higher cell proliferation found in ZG-like ATP1A1/CACNA1D mutant APAs is in agreement with the finding of ATP1A1/CACNA1D (but not KCNJ5 somatic mutations) in aldosterone-producing cell clusters, 31 whereas a low proliferation rate in KCNJ5 mutant APAs is in agreement with studies that found transfection of human adrenocortical cells with KCNJ5 mutations inhibited cell proliferation. 32, 33 Despite our study's capability to detect histopathologic differences between APAs with different genotypes, the sample size limited its detection capability of previously reported slight clinical differences between patients with different mutant APAs. 29 Further, the limitations of the confirmatory test used and retrospective nature of the study may have caused built-in bias. However, if one equates large tumors as KCNJ5 mutant APAs and small tumors as CACNA1D/ATP1A1 mutant APAs, our histopathologic findings have already been replicated by Ono et al's study 34 as he found that APA size correlated with CYP11B1 H score, another enzyme like CYP17A1 that is highly expressed in the ZF, while inversely correlated with CYP11B2 H score. Nevertheless, prospective investigations are needed to verify whether ATP1A1/CACNA1D mutations cause an increase in proliferation rate in APAs (and aldosterone-producing cell clusters) and whether different apoptosis rates in the different genotypes could explain the paradoxical finding of small ATP1A1/CACNA1D mutant APAs having high proliferation rate. We postulate that apoptosis would occur less in KCNJ5 mutant APAs compared with the other genotypes as KCNJ5 mutant APAs have an upregulation of a calcium sensor gene visinin-like 1 (VSNL1), which exerts a protective effect on mutation-related calcium toxicity-induced apoptosis. 35 Correct diagnosis of a unilateral APA is valuable because it gives the opportunity for a patient to undergo a one-off surgical treatment instead of lifelong medical treatments-saving money on healthcare and preventing adverse drug effects and the equally hazardous noncanonical effects of aldosterone that are not inhibited by mineralocorticoid blockers. 36 ZG-like APAs have been reported to be nonclassical and retain responsiveness to the renin-angiotensin system compared with their ZF-like contemporaries, which could lead to confusion with low-renin essential hypertension or PA caused by bilateral hyperplasia. 37, 38 Speculatively, a higher cell turnover rate as indicated by the higher Ki67 expression in ZG-like APAs may facilitate diagnosis of these small nonclassical APAs through making high-read targeted next-generation sequencing of freecirculating adenoma DNA a possibility. Currently, sequencing of free-circulating adenoma DNA has already been tried on patients with the less proliferative KCNJ5 mutant ZF-like APAs. 39 Once a causal mutation for the aldosterone excess is identified, the clinician and patient would be more certain that the resistant hypertension is because of PA, motivating the patient to undergo the invasive procedure, adrenal vein sampling, to ascertain lateralization or at the very least a review of a computed tomographic scan with apparent lack of nodules.
Perspectives
As early as the 1990s, the classical unresponsive ZF-like APAs have been proposed to have a different genetic basis from the nonclassical angiotensin II-responsive ZG-like APAs. 40, 41 This has partly been proven true when KCNJ5 mutant APAs were found to lack a postural aldosterone response and have a predominantly ZF-like cell composition. 13, 42 Like KCNJ5 mutant APAs, we have now shown that ATP1A1 and CACNA1D mutant APAs have a seemingly specific histopathologic phenotype-with ATP1A1/CACNA1D mutant APAs more commonly having a ZG-like cell profile (ie, low expression of CYP17A1, an enzyme highly expressed in ZF and zona reticularis). We, thus, think that genetic diversity could explain morphological, biochemical, and clinical heterogeneity of APAs. We speculate that subtyping of APA (and phenotyping of patient) would allow selection of patients who are most likely to benefit from specific treatments (eg, calcium channel blockers for CACNA1D mutant APAs 4 ), facilitating stratification of PA management. Further, the combination of genotyping and IHC would improve the final histopathologic report whether a single nodule is responsible for the lateralization of aldosterone production or whether it is because of multinodular hyperplasia.
14 Knowledge of an aldosterone-producing multinodular hyperplasia is essential because they are commonly bilateral, forewarning the clinician that an aldosterone-producing lesion may still exist in the remaining contralateral adrenal. This would allow the clinician to undertake appropriate followup measures post-adrenalectomy to pre-empt recurrence of PA through either specific mineralocorticoid blockade or even sparing adrenalectomy of the remaining adrenal.
